Cingulate Inc., a biopharmaceutical company, has filed a prospectus related to the offer and resale of up to 1,500,000 shares of common stock by Lincoln Park Capital Fund, LLC, referred to as the selling stockholder. The shares are par value $0.0001 per share and may be sold at varying prices. Cingulate Inc. may issue and sell these shares to Lincoln Park based on a purchase agreement dated April 24, 2023. The company will not sell any securities under this prospectus and will not receive proceeds from the resale by the selling stockholder. However, Cingulate may receive up to $4,713,220.68 from the sale of shares to Lincoln Park under certain conditions. The selling stockholder may sell the shares in various ways, including on the Nasdaq under the symbol 'CING', where the common stock last reported sale price was $4.81 per share on October 4, 2024. Cingulate is considered an 'emerging growth company' and has recently effected a 1-for-12 reverse stock split. The company emphasizes the speculative nature of this investment and the high degree of risk involved.

Cingulate Inc., a biopharmaceutical company, has filed a prospectus related to the offer and resale of up to 1,500,000 shares of common stock by Lincoln Park Capital Fund, LLC, referred to as the selling stockholder. The shares are par value $0.0001 per share and may be sold at varying prices. Cingulate Inc. may issue and sell these shares to Lincoln Park based on a purchase agreement dated April 24, 2023. The company will not sell any securities under this prospectus and will not receive proceeds from the resale by the selling stockholder. However, Cingulate may receive up to $4,713,220.68 from the sale of shares to Lincoln Park under certain conditions. The selling stockholder may sell the shares in various ways, including on the Nasdaq under the symbol 'CING', where the common stock last reported sale price was $4.81 per share on October 4, 2024. Cingulate is considered an 'emerging growth company' and has recently effected a 1-for-12 reverse stock split. The company emphasizes the speculative nature of this investment and the high degree of risk involved.